Your browser doesn't support javascript.
loading
Recombinant measles virus incorporating heterologous viral membrane proteins for use as vaccines.
Swett-Tapia, Cindy; Bogaert, Lies; de Jong, Pascal; van Hoek, Vladimir; Schouten, Theo; Damen, Irma; Spek, Dirk; Wanningen, Patrick; Radosevic, Katarina; Widjojoatmodjo, Myra N; Zahn, Roland; Custers, Jerome; Roy, Soumitra.
  • Swett-Tapia C; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Bogaert L; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • de Jong P; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • van Hoek V; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Schouten T; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Damen I; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Spek D; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Wanningen P; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Radosevic K; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Widjojoatmodjo MN; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Zahn R; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Custers J; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
  • Roy S; Janssen Vaccines and Prevention, Pharmaceutical Companies of Johnson and Johnson, Leiden, The Netherlands.
J Gen Virol ; 97(9): 2117-2128, 2016 09.
Article en En | MEDLINE | ID: mdl-27311834
ABSTRACT
Recombinant measles virus (rMV) vectors expressing heterologous viral membrane protein antigens are potentially useful as vaccines. Genes encoding the mumps virus haemagglutinin-neuraminidase (MuV-HN), the influenza virus haemagglutinin (Flu-HA) or the respiratory syncytial virus fusion (RSV-F) proteins were inserted into the genome of a live attenuated vaccine strain of measles virus. Additionally, in this case rMV with the MuV-HN or the influenza HA inserts, chimeric constructs were created that harboured the measles virus native haemagglutinin or fusion protein cytoplasmic domains. In all three cases, sucrose-gradient purified preparations of rMV were found to have incorporated the heterologous viral membrane protein on the viral membrane. The possible utility of rMV expressing RSV-F (rMV.RSV-F) as a vaccine was tested in a cotton rat challenge model. Vaccination with rMV.RSV-F efficiently induced neutralizing antibodies against RSV and protected animals from infection with RSV in the lungs.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus Sincitiales Respiratorios / Portadores de Fármacos / Vacunas Virales / Proteínas de la Matriz Viral / Infecciones por Virus Sincitial Respiratorio / Vectores Genéticos / Virus del Sarampión Límite: Animals Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Virus Sincitiales Respiratorios / Portadores de Fármacos / Vacunas Virales / Proteínas de la Matriz Viral / Infecciones por Virus Sincitial Respiratorio / Vectores Genéticos / Virus del Sarampión Límite: Animals Idioma: En Año: 2016 Tipo del documento: Article